Main indication in lupus

- Any lupus patient (cutaneous-articular and / or visceral lupus) should be put, in principle, under Hydroxychloroquine unless contraindicated.

- Hydroxychloroquine has a particular effectiveness on the different forms of cutaneous lupus, but it also reduces the risk of visceral involvement (renal damage in particular) and reduces the risk of sequelae related to the disease. It is associated with longer survival.

Dosage

- 200 mg tablets

- Maximum dose: up to 6.5 mg/kg/d of ideal weight in one to two doses after the meal

Main side effects

- Retinopathy

- Digestive (nausea, pain, vomiting)

- Agranulocytosis

- Neuromuscular with rare myocardial involvement

- Pruritus and rash

- Skin and mucosal coloration

- Hepatitis (rare)

- Mental disorders

In case of pregnancy

No contraindication to the continuation of the treatment (despite what is indicated on the leaflet of the drug that has not been modified since the release of the product). It has been shown that the risk of a flare-up of the disease is lower in women who maintain treatment, and that Hydroxychloroquine is not dangerous for the baby. It protects them particularly if the future mother has anti-SSA antibodies. Can be maintained during breastfeeding.

Contraindications

- Retinopathy (damage to the retina)

- Hypersensitivity to the product

Precautions for use (situations where the drug can be used but with close monitoring)

- Psoriasis

- Hepatic and/or renal insufficiency

- Porphyria

- G6PD enzyme deficiency of congenital origin and exposing to a risk of accelerated destruction of red blood cells

Monitoring

- Ophthalmological examination with a possible electroretinogram/SD OCT depending on the opinion of the ophthalmologist within the first year of use. Annual screening begins after 5 years of use but sooner if presence of major risk factors.- Clinical monitoring